RxDoctor Payments Data

Rohit Marawar, MD

Clinical Neurophysiology · Detroit, MINPI 1447415526

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $39,928 of the $59,812 with a category attached, or 66.8%. Neurelis, Inc. accounts for 76.9% of it on its own, with 12 other manufacturers making up the rest. 2025 is the largest year on record at $39,739, more than ten times the $477 reported in 2019.

$59,812in general payments, 2019–2025

Across 109 payments — averaging $548.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurelis, Inc.$46K
  • SK Life Science, Inc.$6K
  • Eisai Inc.$5K
  • Jazz Pharmaceuticals Inc.$1K
  • UCB, Inc.$340
  • Livanova USA, Inc.$176
  • plus $413 from 7 others
$38,485in research payments, 2019–2025

Across 8 payments — averaging $4810.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eisai Inc.$17K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$11K
  • Catalyst Pharmaceuticals, Inc.$6K
  • Biogen$4K

What the payments were for

  • Consulting fees$8,30014%
  • Speaking & faculty fees$39,92867%
  • Travel & lodging$7,62313%
  • Food & beverage$3,8196%
  • Education$1420%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical neurophysiology providers in Michiganto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$44,077
Medicare patients
194
Services billed
417

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VimpatLacosamide22$44,697
FycompaPerampanel14$19,124
Lacosamide136$13,175
NayzilamMidazolam11$6,891
Oxcarbazepine33$6,104
Levetiracetam82$4,405
Clobazam58$2,702
Carbamazepine ErCarbamazepine19$1,888
Divalproex Sodium34$1,270
Lamotrigine ErLamotrigine14$1,241
Levetiracetam ErLevetiracetam12$762
Risperidone14$562
Donepezil Hcl45$513
Lamotrigine23$443
Propranolol Hcl ErPropranolol Hcl11$364

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Vimpat, Nayzilam$340$51,58833 claims
Eisai Inc.Fycompa$5,279$19,12414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical neurophysiology providers in Michiganon file to place this against a meaningful peer group, so we don't.

Other clinical neurophysiology in Detroit

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →